Exploring the Epigenetics of Dedifferentiation in Liposarcoma Cells

Erica Pimenta, MD, PhD, of the Dana-Farber Cancer Institute, is investigating one of the most complex questions in oncology: the mechanisms driving cancer cell dedifferentiation. This biological process, where mature, specialized cells lose their distinct characteristics and revert to a more primitive, aggressive state, is a universally recognized sign of poor prognosis across both sarcomas and carcinomas. Pimenta’s research published in Science Translational Medicine is premised on the idea that understanding this transition is essential for improving patient outcomes.

The Unique Model of Liposarcoma

Liposarcoma provides a rare and valuable clinical model for studying this phenomenon. The disease often presents with two distinct subtypes within the same patient: well-differentiated and dedifferentiated liposarcoma. Because a well-differentiated tumor can spontaneously transform into a dedifferentiated one despite sharing similar genomics, Pimenta notes that this transition is likely not driven by traditional genetic mutations. Instead, it appears to be an epigenetic event, a change in how genes are expressed rather than a change in the DNA sequence itself.

Innovative Sequencing and Key Findings

To uncover the drivers of this shift, Pimenta’s team utilized single-nucleus multiome sequencing. This advanced technology allows researchers to simultaneously analyze the epigenome and the transcriptome of individual cells, providing a high-resolution map of cellular behavior. The analysis highlighted 2 specific pathways that distinguish the subtypes. Research revealed a stark contrast in insulin-like growth factor 1 (IGF-1) signaling. Although this pathway is highly active in well-differentiated liposarcoma, it is notably absent in the dedifferentiated state.

Most intriguingly, the epigenomic data suggested that dedifferentiated cancer cells are uniquely poised to respond to glucagon-like peptide-1 (GLP-1) signals.

These findings suggest that the loss of differentiation is governed by specific signaling pathways that could eventually be targeted with novel therapies. By focusing on these molecular signatures, Pimenta aims to move toward a more sophisticated understanding of sarcoma biology and the development of interventions that might halt or even reverse cellular dedifferentiation.